| Reproducibility and clinical value of 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma. | |
| | |
MedLine Citation:
|
PMID: 11973489 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The purpose of this study was to assess the reproducibility and clinical impact of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in patients with (suspected) recurrent melanoma. The clinical value of PET was prospectively measured in 58 consecutive patients referred for PET because of unresolved clinical questions after conventional work-up. Diagnostic understanding and therapy choice by referring physicians were evaluated before, directly after, and 6 months after PET. Observer agreement of PET readings was measured with respect to various parameters (interpretation, number and localization of lesions, 'clinically decisive' metastases), using intra-class correlation coefficients. FDG PET improved diagnostic understanding in 33 cases (57%). In six patients (10%), diagnostic understanding was solely based on PET information. According to the attending clinicians, PET contributed to a positive change of planned treatment in 23 patients (40%) and increased confidence in the chosen treatment in 23 (40%). Observer agreement of PET readings was very high (intra-class correlation coefficients were between 0.87 and 0.94). The diagnostic value related especially to the whole-body scan technique and the superior specificity, compared to conventional work-up. It is concluded that, in problematical cases with (suspected) recurrent melanoma, 18F-FDG PET had considerable impact on diagnostic understanding and management. Together with the excellent observer reliability, these results justify further studies to determine the optimal place of PET in routine diagnostic algorithms in recurrent melanoma. |
| | |
Authors:
|
G S Mijnhout; E F I Comans; P Raijmakers; O S Hoekstra; G J J Teule; M Boers; G C De Gast; H J Adèr |
Related Documents
:
|
19756919 - Clinical impact of whole body fdg-pet for recurrent biliary cancer: a multicenter study. 16925579 - Staging performance of carbon-11 choline positron emission tomography/computed tomograp... 20379789 - Integrated pet/ct fusion imaging and endoscopic ultrasound in the pre-operative staging... 8306269 - Comparison of radioimmunodetection with other imaging methods in evaluating local relap... 21070439 - Additional value of pet-ct in staging of clinical stage iib and iii breast cancer. 19156409 - Diagnostic accuracy of contrast-enhanced fdg-pet/ct in primary staging of cutaneous mal... 8327079 - Facial myokymia and spastic paretic facial contracture as the result of anaplastic pont... 7858919 - Trauma to the cerebrovascular system. 6470249 - Improved mr imaging of the upper abdomen with glucagon and gas. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article |
Journal Detail:
|
Title: Nuclear medicine communications Volume: 23 ISSN: 0143-3636 ISO Abbreviation: Nucl Med Commun Publication Date: 2002 May |
Date Detail:
|
Created Date: 2002-04-25 Completed Date: 2002-10-28 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8201017 Medline TA: Nucl Med Commun Country: England |
Other Details:
|
Languages: eng Pagination: 475-81 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine, Vrije Universiteit Medical Centre, Amsterdam, the Netherlands. gs.mijnhout@vumc.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Analysis of Variance False Negative Reactions False Positive Reactions Female Fluorodeoxyglucose F18 / diagnostic use* Follow-Up Studies Humans Male Melanoma / radionuclide imaging* Middle Aged Neoplasm Recurrence, Local / radionuclide imaging* Observer Variation Patient Care / methods* Prospective Studies Questionnaires Radiopharmaceuticals / diagnostic use Reproducibility of Results Sensitivity and Specificity Skin Neoplasms / radionuclide imaging* Statistics as Topic Tomography, Emission-Computed / methods* Whole-Body Counting / methods |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Usefulness of CT scan, MRI and radiocholesterol scintigraphy for adrenal imaging in Cushing's syndro...
Next Document: UK audit of single photon emission computed tomography reconstruction software using software genera...